Reliance Industries has paid $82.6m for a majority stake in NetMeds, an online pharmacy that had raised $99m from backers including Daun Penh Cambodia Group and Sistema.

Sequoia Capital China led a $72.3m round for the drug developer, which counts Xiamen Air and Pien Tze Huang-among its early investors.

Johnson & Johnson, Takeda, Novartis and Bukwang Pharmaceutical all backed the first round disclosed by oncology drug developer Immpact Bio USA.

Hillhouse Capital is set to supply more than $830m for JD.com's pharmaceutical and medical services spinoff, which raised about $1bn last year.

Collaboration partner Gilead Sciences provided $20m as the cancer therapy researcher extended its overall equity funding to $165m.

Portland State University spinout DesignMedix has shut down after its phase 1 trial for an antimalaria treatment caused side effects.

The immuno-oncology company – co-founded by Juno Therapeutics, a spinout of several institutions – is reportedly seeking $250m to $300m in a Hong Kong offering.

PNNL's biomolecule analysis equipment spinout Mobilion Systems will use the funding for recruitment aimed at driving its product roadmap.

WuXi AppTec and Juno Therapeutics' immuno-oncology joint venture is reportedly seeking $250m to $300m in a Hong Kong offering.

Agilent returned for a round that pushed the medical device developer's overall funding past the $50m mark and which will go to commercialising its Slim technology.